Logos Global Management’s Sarepta Therapeutics SRPT Stock Holding History

Logos Global Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-150,000	Closed	-$18.7M	–	68
2024 Q3	$18.7M	Hold	150,000	–	–	2.02%	22
2024 Q2	$23.7M	Sell	150,000 -250,000	-63%	-$32.1M	1.91%	17
2024 Q1	$51.8M	Buy	+400,000	New	+$49M	4.19%	7
2023 Q4	–	Sell	-200,000	Closed	-$19.2M	–	69
2023 Q3	$24.2M	Sell	200,000 -100,000	-33%	-$11.3M	3.23%	10
2023 Q2	$34.4M	Buy	300,000 +80,000	+36%	+$10.3M	4.67%	5
2023 Q1	$30.3M	Hold	220,000	–	–	4.34%	7
2022 Q4	$28.5M	Sell	220,000 -130,000	-37%	-$15.1M	3.34%	13
2022 Q3	$38.7M	Sell	350,000 -50,000	-13%	-$5.04M	4.76%	7
2022 Q2	$30M	Buy	+400,000	New	+$29.4M	5.5%	5
2020 Q4	–	Sell	-275,000	Closed	-$38.6M	–	65
2020 Q3	$38.6M	Buy	+275,000	New	+$41.8M	4.94%	7
2020 Q2	–	Sell	-187,350	Closed	-$18.3M	–	61
2020 Q1	$18.3M	Sell	187,350 -38,652	-17%	-$4.42M	6.97%	2
2019 Q4	$29.2M	Buy	+226,002	New	+$22.8M	7.19%	2

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Logos Global Management's SRPT Position: Q4 2024 in Review

Logos Global Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 150,000 shares — an estimated $18.7M sold.

Logos Global Management first reported a position in SRPT in Q4 2019 and held it in 12 quarters. The position peaked at $51.8M in Q1 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Logos Global Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Logos Global Management sold 150,000 Sarepta Therapeutics shares in Q4 2024, an estimated $18.7M.
Logos Global Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 12 quarters.
Logos Global Management's Sarepta Therapeutics position peaked at $51.8M in Q1 2024.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.